Press Coverage and Latest Announcements


June 11, 2024
Indigenous Pact and DELFI Diagnostics Join Forces to Enhance Lung Cancer Screening in Tribal Communities

June 4, 2024
DELFI Diagnostics Announces Equity Investment from the Merck Global Health Innovation Fund to Accelerate DELFI's Cancer Screening AI Fragmentomics Platform

June 3, 2024
Landmark Blood-Based AI Lung Cancer Screening Test Study Results Published in Cancer Discovery

May 13, 2024
OSF HealthCare and DELFI Diagnostics Announce Collaboration to Improve Lung Cancer Screening Rates

April 2, 2024
City of Hope and DELFI Diagnostics announce collaboration to improve lung cancer screening rates in underserved areas of Los Angeles

April 1, 2024
DELFI Diagnostics to Present at American Association for Cancer Research Annual Meeting

February 1, 2024
DELFI Diagnostics Announces Availability of New Fragmentome-Based Cancer Treatment Monitoring Assay

January 5, 2024
DELFI Diagnostics Appoints Susan Tousi as New Chief Executive Officer

December 13, 2023
DELFI Diagnostics Supports Proposed Legislation to Allow CMS to Review New Blood-Based Screening Tests for Lung Cancer

October 9, 2023
DELFI Diagnostics Launches FirstLook Lung, an Accessible, Accurate New Way to Enhance Lung Cancer Screening Through a Routine Blood Test

October 4, 2023
DELFI Diagnostics to Highlight Breakthrough Technology and Completed Clinical Study in Lung Cancer Detection

July 27, 2023
DELFI Diagnostics Licenses GEMINI Technology from Johns Hopkins University: Study Demonstrates High Performance for Early Stage Lung Cancer Detection When Integrated with DELFI Diagnostics’s Platform

June 1, 2023
DELFI Diagnostics Hires David Morgenstern, PhD, as Vice President of Clinical Development

April 18, 2023
DELFI Diagnostics Presents Additional Promising Proof-of-Concept Data on its Monitoring Program at AACR 2023

March 14, 2023
DELFI Diagnostics to Showcase Breadth of its Next-Generation Liquid Biopsy Platform at the American Association for Cancer Research Annual Meeting

February 23, 2023
DELFI Promotes Jenn Buechel to President and Chief Operating Officer

February 16, 2023
DELFI Hires Lee-Ann Smith-Freeman as Vice President of Legal

November 18, 2022
Positive Liver Cancer Detection Data Published in Cancer Discovery Shows Further Promise of Delfi’s AI Liquid Biopsy Platform

October 27, 2022
Researchers to Present Proof-of-Concept Liver Cancer Detection Data Using the DELFI Platform at AASLD The Liver Meeting® 2022

September 12, 2022
DELFI Diagnostics Selected as the Liquid Biopsy Partner for 4-IN-THE-LUNG-RUN: A Large-Scale European Lung Cancer Screening Study

August 23, 2022
DELFI Diagnostics Adds Finance and Market Access Leadership as it Prepares for Commercial Launch

July 18, 2022
DELFI Diagnostics Announces $225M Series B Financing

July 12, 2022
Jessica Meng Joins DELFI Diagnostics as Chief Commercial Officer

June 22, 2022
DELFI Diagnostics Appoints Jacob Van Naarden to its Board of Directors

May 26, 2022
DELFI Diagnostics to Present at 2022 ASCO Annual Meeting on Multiple Applications for its Next-Generation Liquid Biopsy Platform

May 17, 2022
DELFI Diagnostics Enters into Broad Research Agreement with Top U.S. Cancer Center

May 9, 2022
DELFI Diagnostics Initiates 15,000-Patient Prospective Lung Cancer Screening Trial

April 4, 2022
DELFI Researchers and Founders to Present at American Association for Cancer Research (AACR) 2022 Annual Meeting

March 30, 2022
DELFI Diagnostics Appoints Liz Homans to its Board of Directors

March 24, 2022
DELFI Diagnostics Adds Reimbursement, Regulatory Leaders to Management Team

October 21, 2021
DELFI Bolsters Leadership Team with Three Key Hires

October 7, 2021
Doug Schenkel Joins DELFI Diagnostics as Chief Financial Officer

August 20, 2021
DELFI Liquid Biopsy Shows Promise for Reducing Lung Cancer Deaths

June 23, 2021
Dr. Peter Bach Joins DELFI Diagnostics as Chief Medical Officer

March 31, 2021
DELFI Diagnostics Begins Enrollment for Prospective Lung Cancer Screening Trial Ahead of Planned Commercial Test

February 17, 2021
Industry Leaders Tara Maddala and Allison Ryan Join DELFI Diagnostics Leadership Team

January 12, 2021
DELFI Diagnostics Announces $100 Million Series A Financing to Develop a New Class of Early Detection Liquid Biopsy for Multiple Cancers


Precision Medicine Online
June 21, 2024
Delfi, Indigenous Pact Using Blood Test to Improve Lung Cancer Early Detection in Native Communities

Yahoo Finance
June 7, 2024
Johns Hopkins announces new blood test for early lung cancer detection

June 3, 2024
Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

Los Angeles Daily News
May 31, 2024
City of Hope’s new blood test for lung cancer will mean more early detections

Chicago Tribune
May 10, 2024
A blood test to help detect lung cancer? New test offered at OSF Healthcare part of trend in medicine

The White House
May 1, 2024
FACT SHEET: As Part of the Inaugural National Cancer Prevention and Early Detection Month, Biden Cancer Moonshot Announces New Actions to Strengthen Preventive Cancer Care and Expand Accessibility of Cancer Screenings

Washington Post
April 16, 2024
A blood test to detect cancer? Some patients are using them already

Precision Medicine Online
April 10, 2024
Delfi Diagnostics' Liquid Biopsy Technology Shows Promise for Ovarian Cancer Screening

US News & World Report
April 10, 2024
AI May Bring a Better Blood Test for Ovarian Cancer

April 2, 2024
City of Hope and DELFI Diagnostics announce collaboration to improve lung cancer screening rates in underserved areas of Los Angeles

March 15, 2024
Johns Hopkins Team Debuts New Method for Genome-Wide Detection of Cancer-Linked Repeat Sequences

February 17, 2024
Victor Velculescu, DELFI Diagnostics — Founder Story

February 1, 2024
DELFI Diagnostics Launches Assay That May Improve Monitoring of Cancer Treatment Response

February 1, 2024
Delfi launches cancer-monitoring blood test alongside Immunocore collab

MedTech Dive
January 9, 2024
Susan Tousi leaves Illumina to become CEO of liquid biopsy firm Delfi

Baltimore Business Journal
January 5, 2024
Baltimore biotech backed by more than $300M in funding names new CEO

BNN Breaking
January 4, 2024
Susan Tousi, Illumina CCO, to Helm Delfi Diagnostics as New CEO

January 4, 2024
Illumina chief commercial officer leaves to lead liquid biopsy startup Delfi

January 4, 2024
Updated: Delfi Diagnostics hires Illumina’s chief commercial officer as next CEO

The Cancer Letter
November 17, 2023
Liquid biopsy cancer screening: We’ll need more than one size to fit all

MedTech Strategist
November 14, 2023
Can Delfi Diagnostics Fragmentomics be the key to detecting cancer early?

The Cancer Letter
October 13, 2023
Delfi Diagnostics Commercializes Blood Test for Lung Cancer Screening

Medical Device Network
October 10, 2023
DELFI Diagnostics introduces FirstLook Lung blood test

October 10, 2023
The Readout: Want a biotech buyout? Target cancer

MedTech Dive
October 9, 2023
Delfi launches lung cancer blood test based on DNA fragmentation

October 9, 2023
Delfi Diagnostics launches blood-based lung cancer screening test

October 9, 2023
Delfi launches its blood test to screen for lung cancer – and reveals challenges for liquid biopsies

BioTech TV
October 9, 2023
Delfi Diagnostics' team on launching the FirstLook Lung cancer blood screening test at #HLTH2023

September 26, 2023
BioAffinity Aims to Make Lung Cancer Test Available Nationally Following Pathology Lab Acquisition

September 7, 2023
What a viral study criticizing cancer screening gets very, very wrong

August 22, 2023
DELFI Diagnostics Boost Lung Cancer Detection Power with Addition of Mutation Profiles DELFI Diagnostics Boost Lung Cancer Detection Power with Addition of Mutation Profiles

NCI Cancer Currents Blog
May 15, 2023
Can the New “Omics” on the Block Find Liver Cancer in Blood?

Baltimore Business Journal
May 12, 2023
Raising Baltimore’s Capital

May 4, 2023
‘Are we better off with the information?’: Experts spar over the benefits of liquid biopsy to catch cancer

The Baltimore Sun
January 29, 2023
Baltimore researchers say AI could help reduce disparities, improve access in health care

Baltimore Business Journal
October 7, 2022
Leaders in Health Care 2022: Dr. Victor Velculescu, Delfi Diagnostics

Business Insider
September 6, 2022
21 Most Promising Health Tech Startups According to VCs 2022

San Francisco Business Times
August 30, 2022
Early-cancer detection company takes on billion-dollar competitors

Wall Street Journal
July 18, 2022
Delfi Diagnostics Gathers $225M for Cancer Blood Tests

May 17, 2022
Delfi Diagnostics, Memorial Sloan Kettering Partner to Advance Cancer Screening Technology

Precision Oncology News
May 9, 2022
Delfi Diagnostics Begins Second, Larger Prospective Lung Cancer Screening Trial

Fierce Biotech
March 7, 2022
Fierce Medtech’s 2021 Fierce 15

Fierce Biotech
August 20, 2021
Delfi Diagnostics’ AI-based blood test detects 80% of early-stage lung cancer cases, study finds

Stat News
June 23, 2021
Peter Bach, Industry Critic, Joins Company Aiming to Make Blood Tests to Detect Cancer

March 31, 2021
Delfi Diagnostics Starts Prospective Lung Cancer Screening Trial

January 13, 2021
Delfi Diagnostics Raises $100M for a New Approach to Screening Blood for Cancer

February 5, 2020
Methylation, Fragmentation Analyses Remain at Forefront of Early Detection Liquid Biopsy Development